TME Pharma’s hunt for a partner for its brain cancer drug is closer to bearing fruit as the German biotech clings to its hope of generating $1 billion in peak sales from the asset.
Berlin-based TME said its hunt for a partner for NOX-A12, a CCL2 inhibitor also known as olaptesed pegol, has narrowed down to two suitors. The biotech has now entered the “final evaluation phase of advanced discussions” with two potential partners interested in licensing the asset, according to an Aug. 24 update.
Despite being tight on funds, TME previously managed to take NOX-A12 into a phase 1/2 study for glioblastoma. That study was assessing the CCL2 inhibitor in combination with radiotherapy and Roche’s anti-VEGF drug Avastin.
The company—which entered the year with just 2 million euros ($2.3 million) left in the bank—has a phase 2 study ready to go in Germany, with the trial given the green light in the U.S. But first, a partner is needed.
With TME touting $1 billion in potential peak sales for the drug, the company described NOX-A12 this morning as a “highly valuable flagship drug for treating brain cancer for which there is currently no known cure.”
The aim of the licensing discussions is to find a partner who can take the therapy into phase 2 development, TME explained.
“Our discussions in the last months have yielded concrete strategic interest from two parties,” TME CEO Diede van den Ouden said.
“As we enter the final evaluation phase, our priority is to select the partner and structuring strategy that maximizes both the commercial value of NOX-A12 and its clinical benefit for patients,” van den Ouden added. “We look forward to updating the market as soon as a decision has been made.”
The company previously had a partner for its other key asset—an eye disease drug called NOX-E36 or emapticap pegol—in the form of Singapore Eye Research Institute (SERI). But the institute pulled out in January, less than seven months after forming the collaboration.
The German biotech had been developing the anti-CCL2 RNA aptamer as a potential treatment for a range of ophthalmic indications, including glaucoma filtration surgery, fibrosis and inflammation in the back of the eye.
For now, the company “continues to explore partnering opportunities for NOX-E36,” it explained in today’s release.
Meanwhile, an attempt to branch out beyond biotech has fallen apart. Last year, TME had outlined plans to diversify its investment strategy through a collaboration with an unnamed German company focused on rejuvenating abandoned mining sites in South Africa.
However, TME said this morning it has decided not to continue with this project, even as it remains committed to “search[ing] for sound and future-proof companies and activities.”
Facts Only
* TME is seeking a partner for NOX-A12, a CCL2 inhibitor known as olaptesed pegol.
* The hunt for a partner has narrowed down to two suitors.
* TME entered the "final evaluation phase of advanced discussions" with two potential partners interested in licensing the asset (as of Aug. 24).
* TME previously conducted a phase 1/2 study for glioblastoma using NOX-A12 combined with radiotherapy and Avastin.
* The company has a phase 2 study ready to go in Germany, which received U.S. green light.
* TME projects $1 billion in potential peak sales for the drug.
* The aim of licensing discussions is to find a partner to take the therapy into phase 2 development.
* TME previously had a partner (SERI) for the eye disease drug NOX-E36, but that collaboration ended in January.
* TME is currently exploring partnering opportunities for NOX-E36.
* TME decided not to continue with a planned investment strategy diversification project focused on South African mining sites.
Executive Summary
Full Take
The narrative centers on the tension between high potential clinical value and the necessity of strategic commercial partnership, revealing a classic biotech development challenge: translating promising preclinical/early-stage data into scalable therapies. The focus shifts from internal R&D to external validation and execution, underscored by TME's financial constraints ($2.3 million remaining) juxtaposed against massive market potential ($1 billion peak sales).
The pattern observed is the pivot from single-entity development (SERI partnership ending) to a high-stakes, multi-party negotiation for asset monetization. This reflects a systemic challenge in biotech: optimizing clinical progress requires aligning commercial objectives with scientific milestones. The shift away from diversification efforts signals a strategic narrowing, suggesting that securing optimal terms for NOX-A12 is currently prioritized over broad portfolio expansion.
The implications touch on the role of external partners in realizing patient benefit; success depends not just on finding a licensee but structuring a relationship that balances TME's clinical goals with the partner's commercial appetite and capacity. The decision to proceed or abandon diversification efforts underscores how capital limitations force focus onto the highest-leverage assets, creating an environment where partnership selection becomes a critical gatekeeper for future development.
Bridge Questions: What specific aspects of the licensing structure (e.g., milestone payments versus upfront fees) are most critical for TME's long-term strategic goals? How does the need to secure funding impact the valuation methodology used by TME when evaluating these two suitors? If the SERI partnership failed, what systemic lessons can be drawn regarding the risk profile associated with knowledge transfer in similar collaborations?